Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published:

  • SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

    Endocrine Connections Date published:

  • Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet Date published:

  • Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

    Diabetes, Obesity and Metabolism Date published:

  • Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR

    Clinical Journal of the American Society of Nephrology Date published:

  • The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme

    Diabetes, Obesity and Metabolism Date published:

  • Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas

    PLOS Global Public Health Date published:

  • Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

    Date published:

  • External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials

    Date published:

  • Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD

    Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

    Date published:

  • Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial

    Date published: